ReviewClinical and experimental immunology2014
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.
Review in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies.Arthritis research & therapy · 2026Article
- Malignancy Risk and Predictors in Dermatomyositis and Polymyositis: A Large Population-Based Study.Medicina (Kaunas, Lithuania) · 2025Article
- Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway.Arthritis research & therapy · 2025Article
- ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4 + T cells into Th17 and Treg subsets.Skeletal muscle · 2024Article
- Advance in the mechanism and clinical research of myalgia in long COVID.American journal of clinical and experimental immunology · 2024Review
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Orthopedic Manifestations and Post-COVID-19 Infection.Journal of pharmacy & bioallied sciences · 2023Article
- Delayed skeletal muscle repair following inflammatory damage in simulated agent-based models of muscle regeneration.PLoS computational biology · 2023Article
- Coexistent Relapsing Polychondritis and Clinically Amyopathic Dermatomyositis: A Rare Association of Autoimmune Disorders.Case reports in rheumatology · 2023Article
- Two-dimensional speckle tracking echocardiography demonstrates improved myocardial function after intravenous infusion of bone marrow mesenchymal stem in the X-Linked muscular dystrophy mice.BMC cardiovascular disorders · 2022Article
- Iron controls T helper cell pathogenicity by promoting glucose metabolism in autoimmune myopathy.Clinical and translational medicine · 2022Article
- Cutaneous Manifestations and Their Corresponding Dermoscopic Features in Patients with Dermatomyositis.Dermatology practical & conceptual · 2022Article
- Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population.Vaccines · 2022Review
- The SNPs of mitochondrial DNA displacement loop region and mitochondrial DNA copy number associated with risk of polymyositis and dermatomyositis.Scientific reports · 2022Article
- Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis.Journal of clinical medicine · 2022Article
- Frequency of orthopedic manifestations in COVID-19 patients.Journal of Taibah University Medical Sciences · 2022Article
- Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study.Frontiers in immunology · 2022Article
- Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis: a double-blind, placebo-controlled, cross-over trial.Clinical & translational immunology · 2022Article
- Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic inflammatory myopathies are a heterogeneous group of disorders characterised by diffuse muscle weakness and inflammation. A common immunopathogenic mechanism is the cytokine-driven infiltration of immune cells into the muscle tissue. Recent studies have further dissected the inflammatory cell types and associated cytokines involved in the immune-mediated myopathies and other chronic inflammatory and autoimmune disorders. In this review we outline the current knowledge of cytokine expression profiles and cellular sources in the major forms of inflammatory myopathy and detail the known mechanistic functions of these cytokines in the context of inflammatory myositis. Furthermore, we discuss how the application of this knowledge may lead to new therapeutic strategies for the treatment of the inflammatory myopathies, in particular for cases resistant to conventional forms of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.